Who Might Consider BPC-157 and Who Should Avoid It Based on the preclinical data and clinical patterns of use, the patient populations most commonly prescribed BPC-157 for GI indications include: patients with persistent NSAID gastropathy despite PPI therapy, patients with functional GI symptoms attributed to intestinal barrier dysfunction, and patients with inflammatory bowel disease who have not responded adequately to biologic therapy and seek adjunctive options
Common effects like nausea, diarrhea, and fatigue are typically manageable and may lessen over time, but some side effectssuch as thyroid issues or pancreatitisare rarer and more serious
"If you're a 30-year-old working professional in Delhi, no gym..." 1000mg in the morning on an empty stomach
CO-50 (medical necessity not met) fires when the payer determines the service wasn't medically necessary based on the submitted diagnosis
On the Evidence No clinical trial has tested GHK-Cu in rosacea patients specifically, and any claim citing one should be treated as unverified until a real citation is produced
